Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AIMDW
Upturn stock ratingUpturn stock rating

Ainos Inc. (AIMDW)

Upturn stock ratingUpturn stock rating
$0.11
Last Close (24-hour delay)
Profit since last BUY-52.17%
upturn advisory
WEAK BUY
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/06/2025: AIMDW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.11
high$

Analysis of Past Performance

Type Stock
Historic Profit -86.34%
Avg. Invested days 22
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/06/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2.22
52 Weeks Range 0.03 - 0.31
Updated Date 06/26/2025
52 Weeks Range 0.03 - 0.31
Updated Date 06/26/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2978.02%

Management Effectiveness

Return on Assets (TTM) -30.93%
Return on Equity (TTM) -82.87%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 9206027
Shares Outstanding -
Shares Floating 9206027
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Ainos Inc.

stock logo

Company Overview

overview logo History and Background

Ainos Inc., formerly known as Ainos BioScience, Inc., focuses on developing and commercializing medical technologies. Founded in 2010, the company has evolved from initial research to focus on antiviral and anti-inflammatory treatments and point-of-care diagnostics. Significant milestones include the development of antiviral compounds and diagnostic platforms.

business area logo Core Business Areas

  • Antiviral Therapeutics: Development of novel antiviral therapeutics targeting respiratory infections and other viral diseases. Focuses on formulations and delivery methods to enhance efficacy.
  • Point-of-Care Diagnostics: Developing point-of-care diagnostic devices for rapid and accurate detection of various pathogens and biomarkers.
  • Long-term Care Products: Focuses on products tailored for long term care facilities, including sanitizers and infection control solutions.

leadership logo Leadership and Structure

The leadership team comprises executives with experience in pharmaceuticals, biotechnology, and medical device development. The organizational structure includes research and development, clinical operations, and commercialization divisions.

Top Products and Market Share

overview logo Key Offerings

  • Veldona: Antiviral drug candidate targeting respiratory viruses. Currently in clinical development. Market share data is not yet available as the product is pre-revenue. Competitors in the antiviral space include Gilead Sciences (GILD) and Roche (ROG.SWI).
  • Point-of-Care Diagnostic Platform: A rapid diagnostic platform for detecting infectious diseases. Currently in development. Market share data not available as product is pre-revenue. Competitors include Abbott (ABT) and QuidelOrtho (QDEL).
  • COVID-19 Sanitizers: Offer various sanitization products tailored to the COVID-19 pandemic. No significant market share available, highly competitive market. Competitors include Proctor & Gamble (PG) and Kimberly-Clark (KMB)

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical and diagnostics industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Growing demand for innovative therapies and diagnostics drives market growth.

Positioning

Ainos Inc. positions itself as an innovator in antiviral therapeutics and point-of-care diagnostics. Competitive advantages include proprietary technology platforms and experienced management team.

Total Addressable Market (TAM)

The total addressable market for antiviral therapeutics and point-of-care diagnostics is estimated to be billions of dollars globally. Ainos Inc. is targeting specific segments within these markets, focusing on unmet needs and underserved populations. TAM estimates are between $30-$100 billion.

Upturn SWOT Analysis

Strengths

  • Proprietary antiviral technology platform
  • Experienced management team
  • Focus on unmet medical needs
  • Agile and adaptable business model

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • Limited market presence
  • Pre-revenue stage increases risk

Opportunities

  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Increased demand for point-of-care diagnostics
  • Government funding and grants

Threats

  • Regulatory hurdles and delays
  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Economic downturn impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • ABT
  • ROG.SWI
  • QDEL

Competitive Landscape

Ainos Inc. faces intense competition from established pharmaceutical and diagnostics companies. The company's success depends on its ability to differentiate its products and secure strategic partnerships.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the company's focus on research and development. Growth is anticipated to accelerate upon successful commercialization of its products.

Future Projections: Future growth projections are dependent on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary widely due to the uncertainty surrounding the company's pipeline.

Recent Initiatives: Recent initiatives include advancing clinical trials for Veldona, expanding the point-of-care diagnostic platform, and seeking strategic partnerships.

Summary

Ainos Inc. is a high-risk, high-reward biotechnology company focused on developing antiviral therapeutics and diagnostics. The company's strengths lie in its proprietary technology and experienced management, but its limited financial resources and dependence on clinical trial outcomes pose significant challenges. Successful commercialization of its products is crucial for the company's long-term viability, requiring vigilance about capital.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Press releases
  • Analyst reports
  • Industry reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data and financial projections are subject to change and may not be accurate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ainos Inc.

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2022-08-09
CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai
Sector Healthcare
Industry Medical Devices
Full time employees 44
Full time employees 44

Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.